Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes.

Biomolecules - 21 Aug 2021

Wang Jiun-Long, Tsai Yi-Ting, Lin Ching-Heng, Cidem Abdulkadir, Staniczek Theresa, Chang Gary Ro-Lin, Yen Chih-Ching, Chen Wei, Chong Kowit-Yu, Chen Chuan-Mu

Abstract excerpt

Lung cancer remains a challenge in daily practice. Chemotherapy is first considered for advanced lung adenocarcinoma bearing no active driver mutations. Maintaining drug efficacy and overcoming drug resistance are essential. This study aimed to explore the real-world use of anti-diabetic agent metformin in combination with pemetrexed-based platinum doublets in a first-line setting. We retrospectively collected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Diabetes Complications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus

Share to Metformin

Share to Pemetrexed

Share to Platinum

Share to Probability

Share to Taiwan

Source

Open in PubMed Open full text

Identifiers

PMID: 34439918
DOI: 10.3390/biom11081252
PMCID: PMC8392201

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes.PMID 34439918Read ↗

Does metformin improve the efficacy of standard epidermal growth factor receptor-tyrosine kinase inhibitor treatment for patients with advanced non-small-cell lung cancer?Semantic proximity Read ↗

Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

[Research Progress on the Combination Therapy of EGFR-TKIs and Metformin in Acquired Resistance to EGFR-TKIs in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Association of Diabetes Status With Survival After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: a Retrospective Study in JapanSemantic proximity Read ↗

Chemotherapeutic Agents Increase PD-L1 Expression in A549 Lung Cancer Cell LineSemantic proximity Read ↗

Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.Semantic proximity Read ↗

Comprehensive Analysis of Diabetes Mellitus-related Gene Expression and Associated Prognoses in Human Lung CancerSemantic proximity Read ↗

High Body Mass Index Was Related to Favorable Therapeutic Efficacy of Epidermal Growth Factor Receptor Targeted Therapy in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma.Semantic proximity Read ↗

PD-1 Inhibitor Plus Chemotherapy Versus Chemotherapy for First-Line Treatment in Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Weight change and Impact on prognosis in patients with Advanced Non-small Cell Lung Cancer with Concomitant diabetes mellitus treated with SGLT2 inhibitorsSemantic proximity Read ↗

Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.